Drugs / Bioengineered Artificial Mesenchymal Sheet
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05962931 | Jul 2023 → Jul 2025 | ulcer of lower limbs | Andalusian Network for Design and Translation of Advanced Therapies | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bioengineered Artificial Mesenchymal Sheet | “OBJECTIVE: To evaluate the feasibility, safety and efficacy of the cutaneous application of Bioengineered Artificial Mesenchymal Sheet (BAMS) in venous leg ulcers (VLUs) versus...” PMID 40373055 ↗ May 2025 |
| Known as | BAMS | “OBJECTIVE: To evaluate the feasibility, safety and efficacy of the cutaneous application of Bioengineered Artificial Mesenchymal Sheet (BAMS) in venous leg ulcers (VLUs) versus...” PMID 40373055 ↗ May 2025 |
| Modality | Cell therapy | “This protocol is based on the design of a Phase I/II, multicenter, randomized, controlled, open-label clinical trial investigating the application of a biological dressing...” PMID 40373055 ↗ May 2025 |
| Route | Topical | “The intervention in the treatment group consists of the local application of 4 doses of BAMS, administered once per week” PMID 40373055 ↗ May 2025 |